A recent study has revealed that the SLAB51 formulation, a mixture of bifidobacteria and lactobacilli, can counteract the detrimental effect induced by 6-hydroxydopamine (6-OHDA) in vitro and in vivo models of PD through modulating the BNDF pathway, increasing the PPARγ, activating the Nrf2/HO-1 pathway and inhibiting NFκB, which suggested that SLAB51 can be a promising candidate for PD prevention or treatment or as coadjuvant therapy (Castelli et al., 2020). Here, NFKB1 is linked to Parkinson disease.